title: PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy.
abstract: BACKGROUND
  In hypoparathyroidism, quality of life (QOL) is compromised as compared to normal subjects. We previously reported our results showing an association with recombinant human PTH(1-84) therapy in hypoparathyroidism and improvement in QOL measures for 1 year.
  
  
  OBJECTIVE
  We tested the hypothesis that PTH(1-84) therapy in hypoparathyroidism through 5 years would be associated with continued improvement in QOL measures.
  
  
  METHODS
  Sixty-nine hypoparathyroid subjects received open-label PTH(1-84). Before and during therapy, subjects completed the RAND 36-Item Short Form (SF-36) Health Survey, a measure of health-related QOL covering eight domains of physical and mental health.
  
  
  RESULTS
  At baseline, subjects scored significantly lower than the normative reference range in all 8 domains (T-scores -1.4 to -0.9; P < .001 for all). With PTH therapy, intention-to-treat analysis showed significant improvement in the overall score at 2 months that persisted through 5 years (386 ± 19 to 482 ± 25; P < .0001). The mental component summary score improved at 2 months and was sustained through 5 years (199 ± 11 to 246 ± 14; P = .001), as did all four individual mental health domains and T-scores (vitality, social functioning, role emotional, mental health). The physical component summary score improved at 2 months and was sustained through 5 years (187 ± 10 to 237 ± 13; P < .0001), as did 3 physical health domains and T-scores (physical functioning, role physical, general health).
  
  
  CONCLUSIONS
  PTH(1-84) therapy is not only associated with improvement in biochemical and skeletal indices, previously well-documented, but also in mental and physical health as determined by the SF-36 metric.
authors: Department of Medicine (N.E.C., M.R.R., D.J.M., D.I., L.A., E.L., J.P.B.), Division of Endocrinology, College of Physicians & Surgeons, Columbia University, New York 10032.
authors: Natalie E
authors: NE
authors: Cusano
authors: Mishaela R
authors: MR
authors: Rubin
authors: Donald J
authors: DJ
authors: McMahon
authors: Dinaz
authors: D
authors: Irani
authors: Laura
authors: L
authors: Anderson
authors: Elizabeth
authors: E
authors: Levy
authors: John P
authors: JP
authors: Bilezikian
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004644:Emotions; D005260:Female; D006306:Health Surveys; D006801:Humans; D007011:Hypoparathyroidism / Q000188:drug therapy* / Q000523:psychology*; D008137:Longitudinal Studies; D008297:Male; D008603:Mental Health; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000008:administration & dosage*; D011788:Quality of Life / Q000523:psychology*; D011994:Recombinant Proteins / Q000008:administration & dosage; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D010281:Parathyroid Hormone; D011994:Recombinant Proteins